Role of polymorphisms and microRNA levels in predicting cardiovascular events in patients with acute myocardial infarction

Table 3 Prognostic value of microRNA polymorphism in predicting post-acute myocardial infarction major adverse cardiovascular events

Ref.	Patients (n)	Genetic models	Analyzed model	Population-follow-up period	Standard	HR (95%CI)	P value
Qiao et al[40], 2023	612 ACS	miRNA-146a, rs2910164	Dominant (CC vs CG + GG)	42 months screening for MACE	ABI PRISM3730 DNA Sequencer	1.405 (1.018-1.939)	0.038
			Recessive (CC + CG vs GG)			1.107 (0.821–1.492)	0.506
Li et al[44], 2015	1004 CAD	miRNA-146a, rs2910164	Dominant (CC vs CG + GG)	5 years screening for MACE	PCR-based method	1.119 (0.848-1.478)	0.427
			Recessive (CC + CG vs GG)			1.095 (0.787-1.524)	0.591
			Dominant (CC vs CG + GG)	5 years screening for mortality		0.762 (0.485-1.197)	0.396
			Recessive (CC + CG vs GG)			0.757 (0.398-1.439)	0.203

ABI: Applied Biosystems, Inc; ACS: Acute coronary syndrome; CI: Confidence interval; HR: Hazard ratio; MACE: Major adverse cardiovascular events; miRNA: MicroRNA.